Dynavax Technologies 過去の業績
過去 基準チェック /26
Dynavax Technologiesは、平均年間47.6%の収益成長を遂げていますが、 Biotechs業界の収益は、年間 成長しています。収益は、平均年間19.3% 28.4%収益成長率で 成長しています。 Dynavax Technologiesの自己資本利益率は3%であり、純利益率は7.9%です。
主要情報
47.6%
収益成長率
54.4%
EPS成長率
| Biotechs 業界の成長 | 17.0% |
| 収益成長率 | 28.4% |
| 株主資本利益率 | 3.0% |
| ネット・マージン | 7.9% |
| 前回の決算情報 | 30 Sep 2024 |
最近の業績更新
Recent updates
Dynavax Technologies: What The Stock Buyback Means, What It Doesn't
Nov 13Dynavax Technologies Corporation (NASDAQ:DVAX) Surges 31% Yet Its Low P/S Is No Reason For Excitement
Nov 12
Is Dynavax Technologies (NASDAQ:DVAX) Using Debt In A Risky Way?
Oct 12Dynavax Technologies: Slow And Steady Wins The Race
Sep 05Dynavax Technologies: A Two Trick Pony Operating With A Single Trick
Aug 23Some May Be Optimistic About Dynavax Technologies' (NASDAQ:DVAX) Earnings
Aug 14Is Dynavax Technologies (NASDAQ:DVAX) Weighed On By Its Debt Load?
Jul 12Lacklustre Performance Is Driving Dynavax Technologies Corporation's (NASDAQ:DVAX) Low P/S
May 22Dynavax: HEPLISAV-B Growth Up, Pipeline Uncertain
May 10Dynavax: Holding Firm Despite Its Missing Cash Cow
Mar 23Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?
Mar 06Dynavax Technologies Corporation's (NASDAQ:DVAX) Business And Shares Still Trailing The Industry
Jan 31These 4 Measures Indicate That Dynavax Technologies (NASDAQ:DVAX) Is Using Debt Safely
Aug 02Improved Earnings Required Before Dynavax Technologies Corporation (NASDAQ:DVAX) Shares Find Their Feet
Jun 02We Think Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt With Ease
May 03Dynavax Technologies (NASDAQ:DVAX) Seems To Use Debt Rather Sparingly
Jan 16Clover, Dynavax COVID-19 vaccine gets EU GMP certificate
Sep 20Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?
Sep 12The Alphavaxers: Dynavax And Novavax, 2 Quarters On
Aug 22Dynavax up 8% after raising full-year guidance for key adjuvant product, Q2 beats
Aug 04Are Investors Undervaluing Dynavax Technologies Corporation (NASDAQ:DVAX) By 41%?
Jun 03Dynavax: Evolving Endemic Situation Adds To Its Risk
May 23Dynavax Technologies' (NASDAQ:DVAX) Performance Is Even Better Than Its Earnings Suggest
May 12Dynavax Technologies (NASDAQ:DVAX) Could Easily Take On More Debt
May 10Dynavax Technologies: Full Speed Ahead
Mar 01Here's Why Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt Responsibly
Jan 28収支内訳
収支内訳
Dynavax Technologies の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
| 日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
|---|---|---|---|---|
| 30 Sep 24 | 261 | 20 | 168 | 0 |
| 30 Jun 24 | 250 | 17 | 163 | 0 |
| 31 Mar 24 | 236 | 9 | 159 | 0 |
| 31 Dec 23 | 232 | -6 | 160 | 0 |
| 30 Sep 23 | 361 | 61 | 151 | 0 |
| 30 Jun 23 | 459 | 111 | 143 | 0 |
| 31 Mar 23 | 656 | 236 | 143 | 0 |
| 31 Dec 22 | 723 | 293 | 126 | 0 |
| 30 Sep 22 | 733 | 320 | 124 | 0 |
| 30 Jun 22 | 674 | 228 | 119 | 0 |
| 31 Mar 22 | 470 | 104 | 104 | 0 |
| 31 Dec 21 | 439 | 72 | 92 | 0 |
| 30 Sep 21 | 258 | -39 | 81 | 0 |
| 30 Jun 21 | 163 | -6 | 76 | 0 |
| 31 Mar 21 | 113 | -62 | 73 | 0 |
| 31 Dec 20 | 40 | -75 | 72 | 0 |
| 30 Sep 20 | 38 | -97 | 74 | 0 |
| 30 Jun 20 | 35 | -138 | 72 | 0 |
| 31 Mar 20 | 40 | -129 | 73 | 0 |
| 31 Dec 19 | 35 | -156 | 72 | 0 |
| 30 Sep 19 | 30 | -159 | 70 | 0 |
| 30 Jun 19 | 21 | -163 | 68 | 0 |
| 31 Mar 19 | 14 | -160 | 64 | 0 |
| 31 Dec 18 | 8 | -159 | 65 | 0 |
| 30 Sep 18 | 3 | -146 | 58 | 0 |
| 30 Jun 18 | 1 | -128 | 48 | 0 |
| 31 Mar 18 | 0 | -109 | 40 | 0 |
| 31 Dec 17 | 0 | -95 | 27 | 0 |
| 30 Sep 17 | 8 | -89 | 26 | 0 |
| 30 Jun 17 | 8 | -102 | 32 | 0 |
| 31 Mar 17 | 10 | -111 | 36 | 0 |
| 31 Dec 16 | 11 | -112 | 37 | 0 |
| 30 Sep 16 | 4 | -118 | 36 | 0 |
| 30 Jun 16 | 5 | -113 | 30 | 0 |
| 31 Mar 16 | 4 | -108 | 25 | 0 |
| 31 Dec 15 | 4 | -107 | 22 | 0 |
| 30 Sep 15 | 6 | -102 | 21 | 0 |
| 30 Jun 15 | 7 | -102 | 19 | 0 |
| 31 Mar 15 | 8 | -103 | 18 | 0 |
| 31 Dec 14 | 11 | -91 | 18 | 0 |
| 30 Sep 14 | 12 | -90 | 24 | 0 |
| 30 Jun 14 | 12 | -76 | 24 | 0 |
| 31 Mar 14 | 13 | -68 | 22 | 0 |
| 31 Dec 13 | 11 | -75 | 27 | 0 |
質の高い収益: DVAXは 高品質の収益 を持っています。
利益率の向上: DVAXの現在の純利益率 (7.9%)は、昨年(16.9%)よりも低くなっています。
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: DVAX過去 5 年間で収益を上げており、収益は年間47.6%増加しています。
成長の加速: DVAXは過去 1 年間の収益成長がマイナスであったため、5 年間の平均と比較することはできません。
収益対業界: DVAXは過去 1 年間で収益成長率がマイナス ( -66.5% ) となったため、 Biotechs業界平均 ( 16.6% ) と比較することが困難です。
株主資本利益率
高いROE: DVAXの 自己資本利益率 ( 3% ) は 低い とみなされます。